201 related articles for article (PubMed ID: 26507242)
1. Prediction model for early biochemical recurrence after radical prostatectomy based on the Cancer of the Prostate Risk Assessment score and the presence of secondary circulating prostate cells.
Murray NP; Aedo S; Reyes E; Orellana N; Fuentealba C; Jacob O
BJU Int; 2016 Oct; 118(4):556-62. PubMed ID: 26507242
[TBL] [Abstract][Full Text] [Related]
2. Limited improvement of incorporating primary circulating prostate cells with the CAPRA score to predict biochemical failure-free outcome of radical prostatectomy for prostate cancer.
Murray NP; Aedo S; Fuentealba C; Jacob O; Reyes E; Novoa C; Orellana S; Orellana N
Urol Oncol; 2016 Oct; 34(10):430.e17-25. PubMed ID: 27381896
[TBL] [Abstract][Full Text] [Related]
3. Combining the Prostate Cancer Risk Index (PRIX) with the Presence of Secondary Circulating Prostate Cells to Predict the Risk of Biochemical Failure after Radical Prostatectomy for Prostate Cancer.
Murray NP; Aedo S; Fuentealba C; Reyes E; Jacob O
Asian Pac J Cancer Prev; 2018 Dec; 19(12):3375-3381. PubMed ID: 30583343
[TBL] [Abstract][Full Text] [Related]
4. 10 Year Biochemical Failure Free Survival of Men with CD82 Positive Primary Circulating Prostate Cells Treated by Radical Prostatectomy.
Murray NP; Aedo S; Fuentealba C; Reyes E
Asian Pac J Cancer Prev; 2018 Jun; 19(6):1577-1583. PubMed ID: 29936782
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the Walz Nomogram and Presence of Secondary Circulating Prostate Cells for Predicting Early Biochemical Failure after Radical Prostatectomy for Prostate Cancer in Chilean Men.
Murray NP; Reyes E; Orellana N; Fuentealba C; Jacob O
Asian Pac J Cancer Prev; 2015; 16(16):7123-7. PubMed ID: 26514500
[TBL] [Abstract][Full Text] [Related]
6. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O
J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
[TBL] [Abstract][Full Text] [Related]
7. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
8. Elimination of primary circulating prostate cells after radical prostatectomy for prostate cancer decreases the risk of future biochemical failure.
Murray NP; Reyes E; Orellana N; Fuentealba C; Dueñas R
Arch Esp Urol; 2014 Oct; 67(8):684-91. PubMed ID: 25306986
[TBL] [Abstract][Full Text] [Related]
9. External validation of the CAPRA-S score to predict biochemical recurrence, metastasis and mortality after radical prostatectomy in a European cohort.
Tilki D; Mandel P; Schlomm T; Chun FK; Tennstedt P; Pehrke D; Haese A; Huland H; Graefen M; Salomon G
J Urol; 2015 Jun; 193(6):1970-5. PubMed ID: 25498570
[TBL] [Abstract][Full Text] [Related]
10. [Circulating prostate cells and bone marrow micrometastasis are determinant in risk and time to biochemical progression in localized prostate cancer.].
Murray NP; Aedo S; Fuentealba C; Reyes E; Minzer S; Salazar A
Arch Esp Urol; 2019 Jun; 72(5):471-482. PubMed ID: 31223125
[TBL] [Abstract][Full Text] [Related]
11. Australian validation of the Cancer of the Prostate Risk Assessment Post-Surgical score to predict biochemical recurrence after radical prostatectomy.
Beckmann K; O'Callaghan M; Vincent A; Roder D; Millar J; Evans S; McNeil J; Moretti K
ANZ J Surg; 2018 Mar; 88(3):E183-E188. PubMed ID: 28471003
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of biochemical recurrence-free survival after radical prostatectomy by cancer of the prostate risk assessment post-surgical (CAPRA-S) score.
Aktas BK; Ozden C; Bulut S; Tagci S; Erbay G; Gokkaya CS; Baykam MM; Memis A
Asian Pac J Cancer Prev; 2015; 16(6):2527-30. PubMed ID: 25824791
[TBL] [Abstract][Full Text] [Related]
13. The CPC Risk Calculator: A New App to Predict Prostate-specific Antigen Recurrence During Follow-up After Radical Prostatectomy.
Røder MA; Berg KD; Loft MD; Thomsen FB; Ferrari M; Kurbegovic S; Rytgaard HC; Gruschy L; Brasso K; Gerds TA; Kjær A; Brooks JD; Iversen P
Eur Urol Focus; 2018 Apr; 4(3):360-368. PubMed ID: 28753827
[TBL] [Abstract][Full Text] [Related]
14. Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy.
Punnen S; Freedland SJ; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Carroll PR; Cooperberg MR
Eur Urol; 2014 Jun; 65(6):1171-7. PubMed ID: 23587869
[TBL] [Abstract][Full Text] [Related]
15. Does the Presence of Primary Circulating Prostate Cells Imply the Presence of Agressive Prostate Cancer with Early Biochemical Failure: a Comparison with the Walz Nomogram.
Murray NP; Reyes E; Orellana N; Fuentealba C; Orellana S; Jacob O
Asian Pac J Cancer Prev; 2016; 17(7):3089-93. PubMed ID: 27509934
[TBL] [Abstract][Full Text] [Related]
16. External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment score.
Zhao KH; Hernandez DJ; Han M; Humphreys EB; Mangold LA; Partin AW
Urology; 2008 Aug; 72(2):396-400. PubMed ID: 18372031
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of three risk assessment tools in Australian patients with prostate cancer.
Tamblyn DJ; Chopra S; Yu C; Kattan MW; Pinnock C; Kopsaftis T
BJU Int; 2011 Nov; 108 Suppl 2():51-6. PubMed ID: 22085129
[TBL] [Abstract][Full Text] [Related]
18. PSA density does not improve predictive accuracy of the UCSF-CAPRA score.
Parker R; Bell A; Chang K; Greenberg S; Washington SL; Cowan JE; Carroll PR; Cooperberg MR
Prostate; 2023 Jul; 83(10):922-928. PubMed ID: 37078628
[TBL] [Abstract][Full Text] [Related]
19. Head to Head Comparison of the Chun Nomogram, Percentage Free PSA and Primary Circulating Prostate Cells to Predict the Presence of Prostate Cancer at Repeat Biopsy.
Murray NP; Reyes E; Orellana N; Fuentealba C; Jacob O
Asian Pac J Cancer Prev; 2016; 17(6):2941-6. PubMed ID: 27356715
[TBL] [Abstract][Full Text] [Related]
20. Minimal Residual Disease Defines the Risk and Time to Biochemical Failure in Patients with Pt2 and Pt3a Prostate Cancer Treated With Radical Prostatectomy: An Observational Prospective Study.
Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A; Lopez MA; Minzer S; Orrego S; Guzman E
Urol J; 2020 May; 17(3):262-270. PubMed ID: 31912475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
